Lumos Diagnostics Holdings Ltd. (AU:LDX) has released an update.
Lumos Diagnostics Holdings Ltd. has announced a non-renounceable entitlement offer to raise A$10 million by offering new shares at a 17.4% discount to current shareholders, aiming to fund clinical trials, product development, and general working capital. The offer, lead-managed by Bell Potter Securities Limited, allows shareholders to maintain their ownership percentage and avoid dilution, but non-participating shareholders won’t receive value for unclaimed entitlements.
For further insights into AU:LDX stock, check out TipRanks’ Stock Analysis page.
